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Abstract
Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at spe-
cific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). 
However, along with the clinical benefit provided by these new treatments, new adverse effects have also appeared. Der-
matological toxicities such as papulopustular eruptions, xerosis, and pruritus are common with EGFR inhibitors. Other 
adverse effects have also been described with PDGFR, BCR-ABL, and MAPK tyrosine kinase inhibitors, antiangiogenic 
drugs, and inhibitors at immune checkpoints such as CTLA-4 and PD-1/PD-L1. Onset of these adverse effects often causes 
dose reductions and/or delays in administering the prescribed therapy, which can affect patient survival and quality of life. 
It is, therefore, important to prevent the occurrence of these adverse effects, or to treat unavoidable ones as soon as possible. 
This requires cooperation between medical oncologists and dermatologists. This article reviews the various dermatological 
toxicities associated with targeted therapies and immunotherapies, along with their diagnosis and therapeutic management.
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Introduction
Recent progress in the understanding of cancer biology, 
processes involved in carcinogenesis and neoangiogenesis, 
the tumor/stroma relationship, proliferation, and invasion, 
signaling pathways and the immune response has enabled 
the development of drugs aimed at molecular targets. Targets 
of particular interest include EGFR (epidermal growth factor 
receptor), HER-2, RAS, BRAF, MEK, KIT, RET, mTOR 
(mammalian target of rapamycin), and VEGFR (vascular 
endothelial growth factor receptor) 1, 2, and 3. These new 
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therapies include tyrosine kinase inhibitors (TKI), monoclo-
nal antibodies, and cancer immunotherapies.
The dermatological effects they cause seem to be more 
common than those produced by conventional cytostatics 
and have specific clinical and pathological features [1, 2]. 
EGFR inhibitors are routinely used to treat advanced malig-
nancies such as colorectal cancer and lung cancer. Because 
of their mechanism of action and the targets they attack, they 
are very often associated with the development of derma-
tological adverse effects, which need to be understood and 
managed [3, 4]. However, it must be borne in mind that other 
drugs, directed against targets other than EGFR, also cause 
cutaneous toxicity.
Symptoms and esthetic issues can both have a major 
impact on patients’ quality of life. Patients’ personal, social, 
and workplace relationships can be affected. As with con-
ventional chemotherapy, the dermatological side effects of 
targeted therapies can cause dose reductions and delays, or 
even treatment discontinuation. Accurate diagnosis of these 
adverse effects is, therefore, necessary, and in many cases 
therapeutic measures to reduce their severity and duration 
must be introduced as soon as possible [5, 6]. Preventive 
measures should be applied whenever they exist. Also, mul-
tidisciplinary assessment by dermatologists and medical 
oncologists is key to caring for these patients.
This article reviews the dermatological toxicity associ-
ated with the most commonly used TKIs, monoclonal anti-
bodies, and immunotherapies, together with the clinical 
features, diagnosis, and therapeutic management involved 
with each of them.
Classification of targeted therapies 
and immunotherapies, and mechanism 
of action of cutaneous toxicity
The cancer treatment scene has been revolutionized by 
the advent of new targeted therapies and immunotherapy 
(Table 1). One of their most common side effects is cutane-
ous toxicity, the features of which differ according to each 
drug’s mode of action.
Targeted therapies
EGFR inhibitors
The most important EGFR inhibitors belong to the following 
major therapeutic classes:
• Monoclonal antibodies: cetuximab, panitumumab, and 
necitumumab;
• Tyrosine kinase inhibitors:
– EGFR TKIs (gefitinib, erlotinib, and osimertinib);
– Dual EGFR and HER-2 TKIs (lapatinib and afatinib);
• Multikinase inhibitors (vandetanib).
Antiangiogenic drugs
The two main classes of antiangiogenic drugs are:
Table 1  Classification of targeted therapies and immunotherapies
CTLA-4 cytotoxic T-lymphocyte antigen 4, EGFR epidermal growth factor receptor, mTOR mammalian target of rapamycin, PD-1 programmed 
death 1, PD-L1 programmed death-ligand 1, TKI tyrosine kinase inhibitor, VEGFR vascular endothelial growth factor receptor
Targeted therapies
EGFR inhibitors Monoclonal antibodies against EGFR: cetuximab, necitumumab, and panitumumab
EGFR-specific TKIs: erlotinib, gefitinib, and osimertinib
Dual EGFR and HER-2 kinase inhibitors: lapatinib, afatinib
Less specific multi-kinase inhibitors: vandetanib
KIT and BCR-ABL inhibitors Imatinib, dasatinib, ponatinib, nilotinib, and bosutinib
Antiangiogenic agents Monoclonal antibodies against VEGFR: bevacizumab, ramucirumab, and afliber-
cept
Non-selective antiangiogenic agents: sorafenib, sunitinib, pazopanib, regorafenib, 
axitinib, lenvatinib, cabozantinib, and nintedanib
RAS-RAF-MEK-ERK pathway inhibitors BRAF inhibitors: vemurafenib and dabrafenib
MEK inhibitors: cobimetinib, selumetinib, and trametinib
mTOR inhibitors: sirolimus, everolimus, and temsirolimus
Hedgehog pathway inhibitors Vismodegib
Immunotherapy
Anti-PD-1 Nivolumab, pembrolizumab
Anti-PD-L1 Atezolizumab, durvalumab, avelumab
Anti-CTLA-4 Ipilimumab, tremelimumab
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• Monoclonal antibodies (bevacizumab, aflibercept, and 
ramucirumab);
• Non-selective multikinase inhibitors (sorafenib, suni-
tinib, pazopanib, regorafenib, axitinib, lenvatinib, cabo-
zantinib, and nintedanib).
Multikinase inhibitors characteristically act via several 
pathways, e.g. the platelet-derived growth factor receptor 
(PDGFR), c-KIT, fibroblast growth factor receptor (FGFR), 
RET, and VEGF pathways. The cutaneous toxicity seen with 
multikinase inhibitors reflects the promiscuity of these mol-
ecules, because it derives from their activity on receptors 
other than the VEGF receptors.
KIT, PDGFR, and BCR‑ABL TKIs
The most important drugs in this class are imatinib, dasat-
inib, ponatinib, nilotinib, and bosutinib.
MAPK inhibitors (RAS‑RAF‑MEK‑ERK pathway)
Mitogen-activated protein kinase (MAPK) inhibitors can be 
divided into three drug classes:
• BRAF inhibitors (vemurafenib, dabrafenib, and 
encorafenib);
• MEK inhibitors (trametinib, cobimetinib, and bini-
metinib);
• PI3K-AKT-mTOR pathway inhibitors (sirolimus, everoli-
mus, and temsirolimus).
Hedgehog pathway inhibitors
The main representative of this class of inhibitors is 
vismodegib.
Immune checkpoint inhibitors
The main immune checkpoints are cytotoxic T-lymphocyte 
antigen 4 (CTLA-4), programmed death-ligand 1 (PD-L1), 
and programmed death 1 (PD-1). Inhibitors for each are as 
follows:
• Anti-CTLA-4 (ipilimumab and tremelimumab);
• Anti-PD-1 (nivolumab and pembrolizumab);
• Anti-PD-L1 (atezolizumab, durvalumab, and avelumab).
Papulopustular eruption and xerosis cutis
Both papulopustular eruption and xerosis cutis can occur 
after anti-EGFR drugs or mTOR inhibitors are used.
The underlying mechanism by which these drugs cause 
papulopustular eruption or xerosis cutis is not clear.
Anti‑EGFR drugs
EGFR is mainly expressed and activated in basal keratino-
cytes and in the outer root sheath of hair follicles [7]. 
Arrested hair follicle growth and differentiation as a conse-
quence of therapy can cause mechanical breakage of the hair 
follicle, generating hyperkeratosis and follicular plugging 
[8]. Anti-EGFR drugs can also affect cytokine production, 
resulting in leukocyte chemotaxis and infiltration into the 
skin [9], as well as changes in the skin microflora, giving 
rise to an inflammatory reaction [10].
Papulopustular eruption
Anti-EGFR drug-related papulopustular eruption is char-
acterized by the presence of pruritic papules and pustules, 
typically distributed in seborrheic areas: The scalp, the face, 
behind the ears, in the mid-chest region, and on the shoul-
ders and upper third of the back (Fig. 1a, b). It differs from 
acne in the absence of comedones and the presence of asso-
ciated functional symptoms, such as a burning sensation, 
pruritus or pain. Its location in a highly visible area like 
the face has a major impact on the patient’s emotional and 
social life. It develops during the first and second weeks of 
therapy and peaks between weeks 4 and 6. The eruption 
tends to resolve in approximately 8 weeks, leaving erythema 
and post-inflammatory inflammation (Fig. 1a, b).
Treatment for this condition will depend on the sever-
ity (Table 2). Any therapeutic management must always be 
accompanied by general recommendations: Avoid soaps 
and perfumes, moisturize the skin daily, and apply pho-
toprotection measures (avoid exposure to the midday sun, 
wear appropriate clothing, and use a sunscreen with a high 
UVA + UVB protection factor). For treating localized papu-
lopustular lesions, clindamycin 1% lotions or emulsions and 
moderately to highly potent topical corticosteroids are rec-
ommended. In more extensive cases (grade 2 toxicity), oral 
antibiotics such as doxycycline or minocycline are used. In 
recalcitrant cases, some authors have documented the useful-
ness of oral retinoids, although xerosis and photosensitiv-
ity may worsen in some individuals [11]. Patients who also 
have seborrheic dermatitis of the scalp may benefit from 
shampoos containing ciclopirox olamine 1.5%, ketoconazole 
2%, pyrithione zinc 1%, selenium sulfide, coal tar 0.5% or 
salicylic acid 3–5% preparations.
The eruption caused by anti-EGFR drugs is initially 
sterile, but it is not uncommon for it to be superinfected 
by Staphylococcus aureus, occasionally S. aureus resistant 
to methicillin (MRSA), tetracycline or clindamycin. Her-
pes simplex virus infections are rarely encountered [12]. 
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Faced with a recalcitrant or atypical eruption, or one that 
lasts longer than 8 weeks, bacterial cultures and virological 
tests are recommended, to rule out superinfection and insti-
tute specific treatment [13]. To prevent secondary infection, 
some authors recommend 10-minute baths in dilute bleach 
(a quarter of a cup of household bleach in a bathtub) [13].
The severity of papulopustular eruption has been linked 
to greater overall survival [14–16], with a 60% decrease in 
the risk of death according to a recent meta-analysis [17].
The prophylactic role of tetracyclines has been examined 
in four clinical trials, and the following are recommended: 
minocycline 100 mg once daily, doxycycline 100 mg once 
or twice daily, and tetracycline 500 mg twice daily. In all 
cases, prophylactic treatment has reduced the incidence of 
grade 2 or grade 3 eruptions [18]. Some groups recommend 
phytomenadione (vitamin K) as a topical therapy to prevent 
acneiform eruption [19].
Xerosis and pruritus
Xerosis cutis occurs in up to 35% of patients treated with 
anti-EGFR drugs [20]. Deregulation of epidermal differen-
tiation during anti-EGFR therapy gives rise to an abnormal 
stratum corneum and poor sebaceous gland function, which 
Fig. 1  Papulopustular eruption on the trunk and arms of a patient 
treated with cetuximab for colorectal carcinoma (a, b). Eczematous 
eruption in a patient treated with gefitinib for non-small-cell lung 
cancer (c), Xerosis cutis with skin of an ichthyosis-like appearance in 
a patient treated with everolimus (d)
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results in dry skin [20]. Elderly patients with a history of 
atopic eczema, and individuals previously treated with cyto-
toxic agents, are most likely to develop xerosis. It presents 
as dry, desquamative skin, with an itching sensation. It is 
particularly located in areas simultaneously or previously 
affected by papulopustular eruption. Xerosis can progress 
to chronic asteatotic eczema, with erythematous, desqua-
mative plaques on the trunk and extremities (Fig. 1c). It can 
sometimes be superinfected by S. aureus and, more rarely, 
by herpes simplex virus 1 [10].
Treatment for this condition will depend on its severity 
and extent (Table 2). It essentially involves not applying any 
irritant products to the skin (soaps, perfumes), using oils 
and detergent-free hygiene products, showering in lukewarm 
water, and applying emollient creams daily to help rebuild 
the skin barrier.
Pruritus is suffered by 18–55% of patients on anti-EGFR 
therapy, and the risk is highest with panitumumab [21]. 
Pruritus tends to be associated with papulopustular lesions, 
xerosis cutis or asteatotic eczema. Other factors, such as 
concomitant medication, comorbidities or the underlying 
malignancy itself, can influence the presence of pruritus. In 
cases of mild to moderate pruritus, topical corticosteroids, 
emollient preparations containing antipruritic substances, 
and oral antihistamines can be used. Severe pruritus requires 
oral treatment with antihistamines and corticosteroids, and 
sometimes other drugs with an antipruritic effect, such as 
antidepressants, anticonvulsants and aprepitant [21].
mTOR inhibitors
The inflammatory cutaneous eruptions that occur as a con-
sequence of using these drugs are seen in up to 25% of 
patients on everolimus (< 1% grade ≥ 3) and up to 46% of 
those on temsirolimus (3% grade ≥ 3) [22]. Morbilliform, 
eczematous, and papulopustular eruptions can occur, some-
times in combination with xerosis (Fig. 1d) and pruritus. 
Papulopustular cutaneous eruption occurs during the first 
2 weeks of therapy. It mainly affects the trunk, followed by 
the extremities, neck, face, and scalp. Grading and treatment 
strategies are similar to those recommended for anti-EGFR 
drug-induced eruption (Table 2) [22, 23]. Another similar-
ity to anti-EGFR drugs is that the presence of mucocutane-
ous toxicity has been associated with a better prognosis in 
patients with metastatic renal cell carcinoma treated with 
everolimus [24].
Acral erythema
Differences between acral erythema caused 
by targeted therapies and by conventional 
chemotherapy
Like conventional chemotherapy, targeted therapies often 
affect the skin on the palms of the hands and the soles of 
the feet. However, there are important differences between 
acral erythema caused by targeted therapies and by chemo-
therapy, as summarized in Table 3. Acral erythema induced 
by conventional chemotherapy is a dose-dependent reac-
tion, caused by direct epidermal cytotoxicity. It manifests 
with erythema, edema, fissuring, and blistering [25]. With 
conventional chemotherapy, palmar-plantar involvement 
is often associated with other cutaneous lesions grouped 
together under the term “toxic erythema of chemotherapy” 
[26]. In contrast, TKI-induced hand-foot syndrome mani-
fests with hyperkeratotic lesions on the palms and soles that 
are more severe at pressure points. Although this too is a 
dose-dependent reaction, the pathogenic mechanism has not 
been fully explained [27]. The hand-foot syndrome caused 
by multikinase inhibitors shows no significant association 
with other cutaneous eruptions.
Epidemiology
Hand-foot syndrome is the most common of the cutaneous 
adverse events caused by TKIs. Table 4 lists the drugs most 
often responsible for hand-foot syndrome [27–30].
Table 3  Differences between multikinase inhibitor-induced hand-foot syndrome and acral erythema caused by conventional chemotherapy
PDGFR platelet-derived growth factor receptor, VEGFR vascular endothelial growth factor receptor
Hand-foot syndrome Acral erythema
Common causative agents Regorafenib, cabozantinib, sorafenib, axitinib, sunitinib, 
vemurafenib, pazopanib
Docetaxel, paclitaxel, liposomal doxorubicin, capecit-
abine, fluorouracil, vinorelbine
Pathogenic mechanism VEGFR and PDGFR blockade, difficulty repairing 
microtrauma
Directly cytotoxic to epidermis and eccrine glands
Site of lesions Palms and soles Palms and soles, occasionally dorsum of hands and feet
Clinical features Hyperkeratotic lesions at pressure points Erythema, edema, fissuring, blistering
Histopathology Acanthosis, hyperkeratosis, ballooning degeneration of 
the epidermis, subepidermal blisters
Cell-poor interface dermatitis, epidermal atrophy, 
keratinocyte necrosis, subepidermal blisters with 
epidermal necrosis
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Pathogenesis
The pathogenic mechanism of hand-foot syndrome is 
unknown, although it has been linked to VEGFR and 
PDGFR blockade. It is possible that a defect may occur in 
vascular microtrauma repair, which would explain the ten-
dency for lesions to be located at sites subjected to friction 
[31]. Accordingly, the higher incidence of hand-foot syn-
drome in patients on regorafenib, which uniquely inhibits the 
endothelium-specific TIE-2 receptor (essential in vascular 
remodeling), supports the importance of vascular compe-
tence in the pathogenesis of this syndrome [30].
Clinical features
This is a dose-dependent reaction that occurs in the first 
2–4 weeks of therapy and increases in severity towards the 
second and third months of therapy. The clinical features 
usually tend to abate gradually as treatment continues [27, 
30]. The lesions are located at pressure points on the palms 
and soles, although they can affect other areas subjected to 
friction, such as the knuckles or the sides of the feet. These 
lesions consist of hyperkeratotic plaques situated on an ery-
thematous background, which may even blister in the most 
severe cases. Clinical features include pain and discomfort, 
such as paresthesia, a burning sensation, and reduced heat 
tolerance.
Although hand-foot syndrome is not life-threatening, the 
severity of the discomfort can seriously impair patients’ 
quality of life, and it is a frequent cause of dose reductions 
or early treatment discontinuation.
The severity grading for hand-foot syndrome according 
to the Common Terminology Criteria for Adverse Events 
(CTCAE) is the same as for palmar-plantar erythrodyses-
thesia caused by conventional chemotherapy. Three grades 
are recognized [32]: Grade 1 means the presence of minimal 
skin changes (erythema, edema or hyperkeratosis) without 
associated pain; grade 2 means painful cutaneous lesions 
(blisters, bleeding, edema or hyperkeratosis) hindering eve-
ryday activities; and grade 3 entails painful severe cutaneous 
lesions that make self-care impossible.
Treatment
The tendency should be towards personalized, multidisci-
plinary treatment, involving the medical oncologist, derma-
tologist, podiatrist, and nursing staff. Currently, there are 
no controlled clinical trials available that demonstrate the 
advantages of one treatment over another [33]. Preventive 
measures are important, such as using suitable footwear 
(padded and exerting no pressure), podiatric care, good 
hygiene, applying emollient creams, and avoiding contact 
with anything hot [34]. Gentle keratolytics, such as urea 10% 
or salicylic acid 5%, can be used on hyperkeratotic lesions. 
Erosive or blistered lesions can be treated with hydrocolloid 
dressings. Highly potent topical corticosteroids (clobetasol 
propionate 0.05%) can be used in cases of grade 2 or 3 sever-
ity [34]. Pain is treated with non-steroidal anti-inflamma-
tory drugs or gamma-aminobutyric acid (GABA) agonists. 
Patients with grade 2 or 3 toxicity tend to require treatment 
discontinuations or dose adjustments according to the pro-
tocol for each drug.
Multikinase inhibitor‑induced 
exanthematous reactions
Multikinase inhibitor drugs often give rise to dose-depend-
ent rashes during the first few weeks of therapy [29, 35–37]. 
Unlike the papulopustular eruption seen with anti-EGFR 
drugs, these eruptions are unrelated to efficacy. Multikinase 
inhibitor-induced rashes are not well characterized in the 
literature and are usually described as non-specific rashes. 
They consist of diffuse mild eruptions of a morbilliform, 
eczematous or lichenoid nature, and tend to resolve spon-
taneously despite continued therapy (Fig. 2). They must be 
Table 4  TKIs responsible for hand-foot syndrome
DLT dose-limiting toxicity, FGFR fibroblast growth factor receptor, MAPK mitogen-activated protein kinase, PDGFR platelet-derived growth 
factor receptor, VEGFR vascular endothelial growth factor receptor
Drug Targets Overall incidence of hand-
foot syndrome (%)
Incidence of hand-foot 
syndrome as DLT (%)
Regorafenib [30, 36] VEGFR-1, 2 and 3; TIE-2; FGFR-1; PDGFR-α, β; c-KIT; 
RET; RAF; MAPK
60.5 20.4
Cabozantinib [26, 27] VEGFR-2; c-MET; RET; c-KIT; FLT3; TIE-2 35.3 9.5
Sorafenib [29, 35] VEGFR-2 and 3; PDGFR; ARAF; BRAF; CRAF; FLT3 33.8 8.9
Axitinib [25] VEGFR-1, 2, and 3 29.2 9.6
Sunitinib [29] VEGFR-2; PDGFR; c-KIT; FLT3 18.9 5.5
Vemurafenib [28] BRAF 8.7 2.0
Pazopanib [27] RAF; VEGFR-2 and 3; PDGFR-β; c-KIT; FLT3; RET 4.5 1.8
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distinguished from other much less common, more serious 
eruptions related to drug hypersensitivity, such as erythema 
multiforme, hypersensitivity syndrome, exanthematous 
pustulosis, Stevens-Johnson syndrome or toxic epidermal 
necrolysis. These have all been described occasionally in the 
past with one multikinase inhibitor or another.
Multikinase inhibitor-induced rash is very common. 
It occurs in 20–30% of patients on sorafenib, regorafenib 
or imatinib therapy, 10–20% of patients on sunitinib, and 
5–10% of those on pazopanib therapy. It arises during the 
first 6–8 weeks of treatment and consists of mild eruptions 
(grade 1–2) involving less than 30% of the body surface area. 
The lesions are mainly distributed on the trunk and the tops 
of the limbs. In most cases, the eruptions are eczematous and 
become morbilliform in appearance. Less often, they can 
present as lichenoid lesions. Generally, these eruptions are 
mild (grade 1–2) and do not require withdrawal of the drug. 
If symptomatic treatment elicits a good response, therapy 
can be allowed to continue. The accompanying symptoms 
tend to be pruritus and, occasionally, a pricking sensation. 
Symptomatic treatment with oral antihistamines and mod-
erately potent topical corticosteroids is usually sufficient.
EGFR and BRAF inhibitor‑induced 
abnormalities of the hair follicle and nail 
apparatus
Normal EGFR expression in the epidermis, eccrine glands, 
and hair follicles can encourage development of the PRIDE 
complex (papulopustules, paronychia, regulatory abnor-
malities of the hair follicle, pruritus and dry skin) [38] dur-
ing therapy with EGFR inhibitors. The onset of pustular 
acneiform folliculitis without comedones, sometimes with 
Fig. 2  Sorafenib-induced hand-foot syndrome. Hyperkeratotic lesions on an erythematous background located above pressure points (a, b). 
Sunitinib-induced rash and desquamative maculopapular rash distributed on the trunk (c, d)
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pruritus, occurs on the scalp, face, and trunk in over 50% 
of cases (Fig. 3a), especially during cetuximab and panitu-
mumab therapy, when it is seen in up to 100% of cases [10]. 
This abnormality is usually more severe with the administra-
tion of monoclonal antibodies than with TKIs, and it devel-
ops a week after treatment starts. Although most eruptions 
are grade 1 or 2, higher severity tends to be associated with 
a better tumor response to therapy [4, 10, 38].
Cultures obtained from the lesions are usually negative 
but increased expression of  p27Kip1 in follicular lesions has 
been demonstrated [39]. These lesions, in turn, might be due 
to deregulation of pathways involving IL-1 [40]. Adminis-
tering benzoyl peroxide, metronidazole or clindamycin, or 
adding tetracyclines, oral isotretinoin, or even stopping the 
anti-EGFR drug are the treatment regimens that tend to be 
used most [4, 10, 38].
EGFR inhibitors have also been associated with elonga-
tion (trichomegaly) (Fig. 3b) or fragility of the eyelashes, 
and with more brittle, finer, wavy, and fragile hair [41]. 
BRAF inhibitors, such as vemurafenib, can cause alopecia 
in up to 36% of cases [42]. Last, xerosis cutis may develop 
[4, 10, 38], with substantial morbidity [20], with fissuring 
of the heels (Fig. 3c) or fleshy parts of the digits (Fig. 3d) 
4–8 weeks after therapy with the inhibitor begins [10].
Another side effect related to drugs that inhibit EGFR, 
albeit uncommon, is the onset of nail abnormalities 
4–8 weeks after therapy starts. These take the form of fra-
gility, onychoschizia, onychorrhexis or onycholysis. Only 
10–15% of cases may develop paronychia (Fig. 3e), some-




Pigmentary changes are commonly seen with the admin-
istration of targeted therapies and are often characteristic. 
Essentially, they consist of depigmentation of the hair and, 
to a lesser extent, the skin or its appendages. The c-KIT 
protein is involved in melanocyte physiology, regulating 
melanogenesis and melanocyte proliferation, migration, 
Fig. 3  EGFR inhibitors can cause acneiform folliculitis on the head and trunk (a), elongated eyelashes (trichomegaly) with possibly increased 
eyebrow growth (b), fissures on the heels (c) and fleshy parts of the digits (d), and increased periungual granulation tissue with inflammation (e)
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and survival [43]. Imatinib can cause cutaneous hypopig-
mentation or depigmentation in up to 40% of patients, most 
commonly those with a high phototype [44]. In some cases, 
bluish pigmentation of the oral cavity may be observed [45]. 
Cutaneous depigmentation may be localized or diffuse. It 
develops after several weeks of therapy and usually disap-
pears when treatment ends. In some cases, worsening of 
pre-existing vitiligo, or even hyperpigmentation, has been 
described (Fig. 4a) [46]. Nilotinib and dasatinib can also 
cause pigmentary changes, but less frequently [47].
Sunitinib is a mixed TKI that can produce depigmenta-
tion of the hair, eyebrows or eyelashes after several weeks 
of therapy. This effect is characterized by alternating depig-
mented and pigmented zones on the same hair shaft, corre-
sponding to weeks of therapy and rest periods, respectively. 
It is also common for a yellowish coloration to develop, 
especially on the facial skin and oral mucosa. These changes 
usually resolve when treatment ends [48].
The multikinase inhibitor vandetanib can induce the onset 
of blue-gray macules measuring a few millimeters (blue 
dots), predominantly in perifollicular regions of the face and 
trunk. They tend to persist or recur with maintenance ther-
apy [49]. Pigmentary changes (hyperpigmentation or depig-
mentation) have also been described with immunotherapies 
(interferon, ipilimumab, nivolumab, pembrolizumab), MEK 
inhibitors, and other multi-kinase inhibitors, e.g. pazopanib 
(Fig. 4b, c) [22]. RAF inhibitors (sorafenib, vemurafenib, 
dabrafenib, and regorafenib) can induce dynamic changes 
in pre-existing naevi or trigger the development of eruptive 
naevi (Fig. 4d). Dermatological surveillance is necessary in 
this context, because cases of de novo primary melanomas 
have been reported in patients treated with BRAF inhibitors 
[50].
Impaired healing due to antiangiogenic 
drug use
Inhibition of angiogenesis interferes with normal skin home-
ostasis. Among other complications, this can give rise to 
delays or difficulties in wound healing. Drugs that inhibit 
VEGF or VEGFR have the potential to cause these compli-
cations. Bevacizumab, an anti-VEGF antibody, is associated 
with a higher incidence of surgical wound complications 
(dehiscence and delayed healing). The incidence varies 
according to the context in which it is used. It is advisable 
to stop treatment with this drug at least 6–8 weeks before 
surgery and to wait until 4 weeks after surgery before resum-
ing it [51]. The risk of complications with mTOR inhibitors 
is not negligible either. It is, therefore, advisable to stop ther-
apy 7–10 days beforehand and to wait for at least 3 weeks 
after the intervention before resuming it. The risk seems to 
Fig. 4  Worsening of pre-existing vitiligo (a), immunotherapy-induced vitiligo and depigmentation (b, c), and BRAF inhibitor-induced eruptive 
naevi (d)
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be lower with TKIs. The recommendation is to stop them 
24–48 h before surgery and to wait 3–4 weeks before resum-
ing them [52]. In any case, good perioperative management, 
bearing in mind the elimination half-life of each drug, is 
essential to avoid these complications [53].
Neutrophilic dermatosis
The onset of various neutrophilic dermatoses has been 
described with the use of targeted therapies. TKIs, such as 
imatinib, nilotinib or dasatinib, have been linked to cases 
of Sweet’s syndrome, neutrophilic eccrine hidradenitis, and 
neutrophilic panniculitis [54]. Pyoderma gangrenosum has 
also been linked to TKIs, EGFR inhibitors, and drugs such 
as ipilimumab or rituximab, among others [55]. Cases of 
neutrophilic eccrine hidradenitis and neutrophilic pannicu-
litis have also been reported in patients on BRAF inhibitors 
(vemurafenib, dabrafenib). In most cases, treatment discon-
tinuation tends not to be necessary [56].
Cutaneous lesions caused by BRAF and MEK 
inhibitors
In pivotal trials conducted with vemurafenib, a BRAF inhib-
itor, a high percentage of patients developed side effects, 
mainly of a cutaneous nature (92–95%) [28]. Nevertheless, 
most of these effects are mild or moderate, and relatively 
easy to manage if well understood. Very few cases require 
modification or discontinuation of therapy. The occurrence 
or severity of these side effects has not been correlated with 
treatment efficacy.
The cutaneous side effect of greatest concern is the 
onset of skin tumors, specifically squamous cell carcino-
mas (Fig. 5a) and, in many cases, a well-differentiated vari-
ant of these with very little metastatic potential, called a 
keratoacanthoma. These tumors generally appear between 
weeks 2 and 36, most commonly between weeks 12 and 
18. They have been reported in 20–30% of patients [22]. 
Surgical treatment for these tumors is usually simple. The 
administration of oral retinoids has been shown to reduce 
their frequency [57]. Their occurrence seems to be due to 
Fig. 5  A patient with squamous cell carcinoma of the upper lip, keratosis pilaris, and plantar keratoderma secondary to vemurafenib therapy (a, 
b, and c, respectively). Reactivation of psoriasis in a patient on pembrolizumab therapy (d)
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paradoxical stimulation of the MAPK pathway in BRAF 
wild-type cells [58]. This stimulation is especially impor-
tant in cells that, because of sun exposure, already harbor 
mutations in RAS, the first kinase in this pathway. Other 
BRAF inhibitors developed subsequently, such as dab-
rafenib, cause cutaneous side effects, including squamous 
cell carcinomas, at a lower rate [59]. Introducing dual inhi-
bition of the MAPK pathway with coadministered BRAF 
and MEK inhibitors has achieved a substantial reduction 
in the frequency at which these tumors occur, probably by 
inhibiting the paradoxical stimulation described above, by 
means of MEK inhibitor-induced blockade of the pathway 
downstream of BRAF [60]. The onset of both atypical mel-
anocytic lesions and melanomas of low thickness has also 
been documented. These have been attributed to the same 
paradoxical MAPK pathway stimulation effect [61].
Despite the above, the most common cutaneous mani-
festation is a maculopapular rash (64–75% of cases), often 
poorly described [28]. Of particular note is the follicular 
accentuation shown by the lesions in some cases, taking 
on the appearance of keratosis pilaris [22] (Fig. 5b). Other 
patients develop a rash composed of erythematous papules 
located on the chest, face, and upper limbs. Biopsy has 
demonstrated the existence of acantholysis and suprabasal 
dyskeratosis, findings consistent with Grover’s disease (or 
transient acantholytic dyskeratosis) [62, 63]. These lesions 
have been attributed to paradoxical MAPK pathway activa-
tion in normal keratinocytes, causing decreased expression 
of the protein sarco/endoplasmic reticulum  Ca2+-ATPase 
type 2 isoform (SERCA2), also involved in Darier’s disease, 
which shares histological features in common with Grover’s 
disease [63].
Photosensitivity is another common side effect of vemu-
rafenib (35–63% of patients) [28]. This drug stimulates 
erythrocyte 5-aminolaevulinic acid synthase (ALAS), rais-
ing porphyrin levels in red blood cells [64]. Photobiology 
tests have shown the photosensitivity to be due to a height-
ened reaction to ultraviolet rays (UVA), with a decrease 
in the UVA minimal erythema dose [64, 65]. Other less 
common side effects are: palmar-plantar erythrodysaesthe-
sia (8–10% of patients) [28]; palmar-plantar keratoderma 
(6–60% of patients), which can cause substantial discomfort 
in daily life [22] (Fig. 5c); alopecia due to telogen effluvium; 
and changes in the appearance of the hair, ranging from turn-
ing gray to becoming curly [66].
One uncommon but very interesting side effect already 
mentioned above is the onset of neutrophilic dermatoses 
during the administration of BRAF inhibitors. There have 
been reports of lobular panniculitis, Sweet’s syndrome, and 
neutrophilic eccrine hidradenitis [67–69].
Side effects related to MEK inhibitors (trametinib, cobi-
metinib) are less complex. The most common are papulopus-
tular rashes (77–89% of patients) and xerosis (30%) [22, 62].
Cutaneous lesions caused by cancer 
immunotherapy
In the past few years, progress in the understanding of 
regulatory mechanisms governing the immune response 
has led to the development of monoclonal antibodies that 
deactivate inhibitory receptors expressed by T cells. Drugs 
that stimulate the immune response by inhibiting CTLA-4 
(ipilimumab), PD-1 (nivolumab, pembrolizumab) or 
PD-L1 have thus appeared. However, the anticancer effect 
of these drugs is accompanied by a number of cutaneous 
and systemic side effects related to immune stimulation. 
In this class, cutaneous side effects are the most common, 
and they also tend to be the first to appear. Although their 
severity seems to be correlated with treatment efficacy, 
their absence does not imply lack of response. In general, 
they are reversible if treated promptly, and the administra-
tion of either systemic corticosteroids or anti-TNF drugs 
does not counteract the anticancer effect [70]. The most 
common cutaneous side effects are the same with either 
anti-CTLA-4 or anti-PD-1 drugs: maculopapular rash, pru-
ritus, and vitiligo. They occur more often and are more 
severe with ipilimumab than with anti-PD-1 drugs.
In the case of ipilimumab, and unlike the situation with 
anti-PD-1 drugs, cutaneous side effects depend on the 
drug dose. The most common side effect is maculopapu-
lar rash (47–68%) [62]. It tends to occur 2–5 weeks after 
therapy begins. Severe, life-threatening reactions, of the 
Stevens-Johnson syndrome, toxic epidermal necrolysis or 
DRESS syndrome type, have been reported at a frequency 
of less than 1% [70]. Pruritus can occur on its own, or 
in the context of the above-mentioned rash, and may be 
severe enough to require dose reduction. Dermatomyosi-
tis, Sweet’s syndrome, pyoderma gangrenosum, and sar-
coidosis have been described during anti-CTLA-4 therapy, 
albeit uncommonly [71–74].
As far as the most common reactions related to anti-
PD-1 drugs are concerned, the maculopapular rash often 
acquires lichenoid features (lesions with a dark red tone 
and intense residual hyperpigmentation). A biopsy con-
firms lichenoid histology [75, 76]. On the other hand, 
achromic lesions resembling vitiligo have often been 
described. Unlike vitiligo, however, they tend to adopt 
a patchy distribution, occur more often in light-exposed 
areas, and do not display the Koebner phenomenon [77]. 
An ever-increasing number of publications describe 
patients who were diagnosed with pemphigoid after com-
mencing anti-PD-1 therapy [78]. Last the triggering of 
psoriasis flare-ups has also been linked to this drug class, 
in most cases in patients with a history of this disease [79, 
80] (Fig. 5d).
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Grading cutaneous toxicity in cancer 
patients on targeted therapies 
and immunotherapy, and dose adjustments
New cancer treatments, including immunotherapy, cause a 
range of cutaneous toxicities that can lead to dose changes 
or discontinuation of various drugs. The constant addition 
of new substances and their combinations, especially in 
clinical trials, poses a challenge, in terms of both grading 
toxicities and managing them with specific dermatological 
treatment. Notable scales for grading cutaneous toxicity 
include the Common Terminology Criteria for Adverse 
Events (CTCAE), Version 4.03 [32, 81], produced by the 
National Cancer Institute (NCI) and, more recently, the 
Multinational Association of Supportive Care in Cancer 
(MASCC) EGFR Inhibitor Skin Toxicity Tool (MESTT) 
[82].
The CTCAE and MESTT scales grade dermatological 
toxicities from 1 to 5. As a general rule, a grade 1 toxicity 
is asymptomatic or involves few symptoms, which only 
requires diagnostic and clinical observation, and needs no 
specific treatment. Grade 2 or moderate toxicity requires 
non-invasive, local treatment. Grade 3 is severe, and the 
patient must be admitted to hospital. Grade 4 requires 
urgent treatment for a life-threatening condition, and 
Grade 5 means the patient died from the adverse effect.
The dermatological toxicity most often seen with targeted 
therapies relates to anti-EGFR drugs. It is caused by EGFR 
inhibition in the skin, and the most common form is papu-
lopustular eruption [83, 84]. With immunotherapies, der-
mal toxicity occurs in 40–45% of patients, normally between 
weeks 3 and 6 of therapy [85, 86]. Whether to adjust or delay 
the dose or discontinue treatment is specified in the pre-
scribing information for each drug. In general, we describe 
the steps to be taken according to drug class and the most 
representative toxicities. For EGFR inhibitors, the dose 
should be adjusted after the onset of cutaneous toxicity of 
grade 3 or above, or intolerable grade 2 toxicity. In these 
cases, treatment should be discontinued temporarily until 
the toxicity subsides to grade 1 or 2, respectively. It should 
then be resumed at a lower dose [87].
Monoclonal antibodies against VEGF/VEGFR cause 
delayed healing. The most representative drug of this class is 
bevacizumab. Withdrawal is recommended 6–8 weeks prior 
to planned surgery, followed by reintroduction 4 weeks after 
the operation. In the antiangiogenic drug class, in the case 
of multikinase inhibitors, it is recommended that therapy be 
discontinued 24–48 h prior to surgery, and 3–4 weeks should 
elapse before treatment resumes [52]. In all cases, therapy 
should stop until the wound is completely healed.
Hand-foot syndrome is also common and limiting with 
this drug class. Dose reduction is recommended if it occurs 
at grade 2. If it persists, or reaches grade 3 or above, the 
drug should be discontinued until the condition improves.
In the case of the RAF inhibitors vemurafenib and dab-
rafenib, the onset of cutaneous squamous cell carcinomas 
and new primary melanomas is managed by monitoring 
these new lesions and removing them surgically, with no 
need for dose modification.
With the mTOR inhibitors everolimus and temsirolimus, 
given the risk of dehiscence at the suture site, it is recom-
mended that therapy be discontinued 7–10 days prior to 
surgery, and resumed not less than 3 weeks afterwards [52].
Last, during immunotherapy, the most common cutane-
ous toxicities are maculopapular rash, pruritus, and viti-
ligo. For clinical practice, it is suggested that grade 1 and 
mild grade 2 toxicities should be managed with supportive 
measures, and immunotherapy can continue. In the event of 
grade 3 or highly symptomatic grade 2 toxicities, the recom-
mendation is to discontinue therapy temporarily until the 
symptoms become mild or have disappeared. It is then pos-
sible to resume it, once the risks and benefits have been dis-
cussed with the patient. With grade 4 toxicities, the therapy 
needs to be withdrawn permanently and the patient assessed 
urgently by a dermatologist [88].
Once the existence of cutaneous toxicity of grade 2 or 
above has been confirmed, the patient should be referred to 
the dermatology department, to commence specific treat-
ment to improve the symptoms. Follow-up should take place. 
In the event of deterioration, the patient should be admitted 
to hospital and/or managed specifically as appropriate [81].
Conclusions
It is common for dermatological toxicities to occur while 
cancer patients are being treated with targeted therapies. 
Their onset may cause dose reductions and/or delays in treat-
ment, thus compromising patient survival. Also, this toxicity 
has a significant impact on patients’ quality of life and can 
affect their personal, social, and workplace relationships.
Cutaneous toxicity is most common with EGFR inhibi-
tors, but it is not confined to this drug class. It also occurs 
with the use of TKIs, PDGFR, and BCR-ABL inhibitors, 
antiangiogenic drugs such as the monoclonal antibodies bev-
acizumab and ramucirumab, MAPK inhibitors, and immune 
checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1/
PD-L1 drugs.
The dermatological syndromes most often associated 
with these therapeutic targets are as follows: papulopustular 
eruption, the onset of which, in the case of anti-EGFR drugs, 
is related to greater overall survival; xerosis, and pruritus, 
sometimes combined with the above; hand-foot syndrome; 
rashes, often linked to multikinase inhibitors, and unrelated 
to efficacy in this case; abnormalities of the hair follicle 
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and nail apparatus, linked to anti-EGFR drugs; pigmentary 
changes to the skin and its appendages; impaired healing 
due to antiangiogenic drug use; and neutrophilic dermatoses.
The toxicities most often caused by immunotherapy, with 
either anti-CTLA-4 or anti-PD-1/PD-L1 drugs, are maculo-
papular rash, pruritus, and vitiligo.
Whenever possible, these symptoms should be prevented. 
Accurate and prompt diagnosis is essential. Additionally, 
interdisciplinary cooperation between oncologists and der-
matologists is critical to reduce the duration and severity of 
cutaneous toxicity, to optimize the delivery of therapy, and 
to improve patient survival.
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